عنوان

Heart Failure :

(Number (ISBN

1420030868

(Number (ISBN

9781420030860

Number

b600301

Title Proper

Heart Failure :

General Material Designation

[Book]

Other Title Information

A Comprehensive Guide to Diagnosis and Treatment.

First Statement of Responsibility

G William Dec

Name of Publisher, Distributor, etc.

London CRC Press

Date of Publication, Distribution, etc.

2004. ©2004.

Specific Material Designation and Extent of Item

(600 pages).

Series Title

Fundamental and clinical cardiology.

Text of Note

16 New Pharmacologic Therapies in Heart Failure: Immunotherapy, Endothelin-1 Antagonists, Brain Natriuretic Peptides, and Neurohormonal Interventions.

Text of Note

Bradykinin-Prostaglandin and Other Pathways --; Effects on Hematocrit --; Electrophysiological and Autonomic Effects --; Uricosuric Effect --; Tolerability --; Will the Combination of ACE inhibitors and ARBs Prove Superior to Either Class Used Alone? --; The Question of Dose --; LANDMARK TRIALS AND META-ANALYSES PRINCIPALLY DESIGNED TO COMPARE ARBS WITH PLACEBO IN THE ABSENCE OF AN ACE INHIBITOR --; The Losartan Meta-Analysis --; The Candesartan Meta-Analysis --; CHARM-Alternative --; CHARM-Preserved --; I-PRESERVE --; LANDMARK TRIALS PRINCIPALLY DESIGNED TO COMPARE ARBS WITH PLACEBO IN THE PRESENCE OF AN ACE INHIBITOR --; RESOLVD --; Val-HeFT --; CHARM-Added --; VALIANT --; LANDMARK TRIALS PRINCIPALLY DESIGNED TO COMPARE ARBS WITH ACE INHIBITORS --; ELITE (Evaluation of Losartan in the Elderly Study) --; ELITE II --; RESOLVD --; OPTIMAAL --; VALIANT --; WHY USE AN ARB? To Improve Symptoms of Heart Failure --; To Reduce Hospitalization --; To Reduce Major Vascular Events --; To Reduce Mortality --; Adverse Effects --; Are the benefits and side effects of ARBs dose related? --; Are There Clinically Relevant Differences Between ARBs? --; Are There Important Interactions Between ARBs and Other Classes of Drug Used in Heart Failure? --; Heart Failure in the Absence of Left Ventricular Systolic Dysfunction --; CONCLUSIONS --; REFERENCES --; 15 Role of Mineralocorticoid Antagonists in Patients with Heart Failure --; SYNOPSIS --; INTRODUCTION --; THE EFFECT OF ALDOSTERONE RECEPTOR ANTAGONISTS ON SODIUM EXCRETION AND DIURESIS --; EFFECTS OF MR ANTAGONISTS ON VENTRICULAR REMODELING --; ALDOSTERONE AS AN INFLAMMATORY MEDIATOR --; EFFECTS OF MR ANTAGONISTS ON VASCULAR TONE --; PREVENTION OF SUDDEN CARDIAC DEATH --; EFFECTS ON THE AUTONOMIC NERVOUS SYSTEM --; MYOCARDIAL FIBROSIS --; EMERGING THEMES IN MR ANTAGONISM: IS IT THE LIGAND, THE RECEPTOR, OR BOTH? --; CONCLUSION --; REFERENCES.

Text of Note

Front cover --; Preface --; Contents --; Contributors --; 1 The Genetics of Dilated and Hypertrophic Cardiomyopathies --; GENETIC METHODS --; Familial Aggregation --; Genetic Linkage --; Clinical Diagnosis and Genetic Mapping --; Positional Cloning --; Genetic Association Studies --; Locus and Allelic Heterogeneity --; Modifiers of Simple Traits --; USING GENETICS IN CLINICAL PRACTICE --; Family-Based Diagnosis --; Diagnosis-History --; Diagnosis-Clinical Evaluation --; Prognosis --; Management --; SPECIFIC DISORDERS-DILATED CARDIOMYOPATHY --; Etiology of DCM --; Clinical Genetics --; Genetic Mapping --; Molecular Genetics and Pathophysiology --; Disease Models --; HYPERTROPHIC CARDIOMYOPATHY Definitions and Clinical Features --; Clinical Genetics --; Molecular Genetics --; Disease Models --; CONCLUSION --; REFERENCES --; 2 Molecular Signaling Networks Underlying Cardiac Hypertrophy and Failure --; INTRODUCTION --; THE SIGNAL AT THE CELL MEMBRANE --; Mechanical Deformation --; Humoral Factors --; SIGNALING WITHIN THE CELL --; Reprogramming of Gene Expression --; In-Depth Evaluation of Calcineurin-Nuclear Factor of Activated T-Cell Signaling --; Use of CsA and FK506 in Animal Models of Cardiac Hypertrophy --; Targeted Inhibition of Calcineurin Attenuates Hypertrophy --; Calcineurin Targets Regulating the Hypertrophic Response --; Clinical Use of CsA and FK506 --; Regulation of Protein Synthesis --; Evaluation of mTOR --; The PI3-K Pathway --; Other Pathways Involved in Growth Regulation --; ALTERATIONS IN SIGNALING IN THE DISEASED HUMAN HEART --; REFERENCES --; 3 Mechanisms of Cell Death in Heart Failure --; MORPHOLOGIC FEATURES OF CELL DEATH --; CELL DEATH BY NECROSIS IN HEART FAILURE --; CELL DEATH BY APOPTOSIS IN THE FAILING MYOCARDIUM --; ROLE OF UBIQUITIN-PROTEOSOME PATHWAY IN MYOCYTE DEATH IN HEART FAILURE --; CROSS-TALK IN DEATH PATHWAYS --; CONCLUSIONS --; REFERENCES. 4 Excitation-Contraction Coupling Mechanisms in Heart Failure --; SUMMARY --; EXCITATION-CONTRACTION COUPLING --; Electrical Activity in the Heart --; Regulation of Contractility in the Heart --; CHANGES IN HEART FAILURE --; Action Potential and Repolarizing Currents in Heart Failure --; Calcium Handling in Failing Hearts --; Contractile Proteins --; Energetics --; Abnormal --; receptor Signaling --; CONCLUDING REMARKS --; REFERENCES --; 5 B- Adrenergic Signaling in Heart Failure --; INTRODUCTION --; ADRENERGIC RECEPTORS-MORE THAN REGULATORS OF CARDIAC CONTRACTILITY --; GRK Arr --; AC --; TARGETS OF --; ADRENERGIC RECEPTOR STIMULATION --; CHANGES OF --; ADRENERGIC SIGNAL TRANSDUCTION IN HEART FAILURE --; BLOCKERS AS THERAPEUTIC PRINCIPLE IN HEART FAILURE --; MUTATIONS IN ADRENERGIC RECEPTOR GENES LEADING TO ALTERED SIGNALING PROPERTIES --; ACKNOWLEDGEMENTS --; REFERENCES --; 6 Ventricular Remodeling and Secondary Valvular Dysfunction in Heart Failure Progression --; PATHOGENESIS OF VENTRICULAR REMODELING --; FUNCTIONAL CHANGES --; NEUROHORMONAL ACTIVATION --; CELLULAR AND SUBCELLULAR CHANGES IN REMODELING --; EXTRACELLULAR MATRIX DEGRADATION --; MYOCYTE HYPERTROPHY AND APOPTOSIS --; FIBROSIS --; REMODELING CHANGES ON THE MACROSCOPIC LEVEL --; SECONDARY VALVULAR DYSFUNCTION --; REMODELING AND VALVULAR DYSFUNCTION OF THE RIGHT VENTRICLE --; THERAPEUTIC TARGETS --; REFERENCES --; 7 Neurohormonal and Cytokine Activation in Heart Failure --; SYNOPSIS --; INTRODUCTION --; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM --; SYMPATHETIC ACTIVATION --; INTERACTION OF RENIN ANGIOTENSIN AND SYMPATHETIC ACTIVATION --; CYTOKINE ACTIVATION --; REGULATION OF PLASMA VOLUME --; VASCULAR REACTIVITY --; CLINICAL HETEROGENEITY IN HEART FAILURE: IMPACT OF GENETIC DIVERSITY --; SUMMARY --; ACKNOWLEDGEMENT --; REFERENCES --; 8 Cardiomyopathies in the Adult (Dilated, Hypertrophic, and Restrictive) --; INTRODUCTION. DILATED CARDIOMYOPATHY Morphology and Pathology --; Epidemiology and Natural History --; Etiology --; Clinical Presentation --; Evaluation --; Treatment --; HYPERTROPHIC CARDIOMYOPATHY Morphology and Pathology --; Epidemiology and Natural History --; Etiology --; Clinical Presentation --; Evaluation --; Management --; RESTRICTIVE CARDIOMYOPATHY Morphology and Pathology --; Epidemiology, Natural History, and Etiology --; Clinical Presentation --; Evaluation --; Management --; SUMMARY --; REFERENCES --; 9 Heart Failure with Normal Systolic Function --; INTRODUCTION --; PATHOPHYSIOLOGY OF DIASTOLIC HEART FAILURE --; DIAGNOSING DIASTOLIC HEART FAILURE --; Objective Evidence of Congestive Heart Failure --; Objective Evidence of Normal Left Ventricular Systolic Function --; Objective Evidence of Left Ventricular Diastolic Dysfunction --; Clinical Improvement by Treating Precipitating Factors --; Diagnosing Diastolic Heart Failure at the Bedside --; PREVALENCE --; THE ETIOLOGY --; Hypertension --; Left Ventricular Hypertrophy --; Myocardial Fibrosis --; Coronary Artery Disease --; Diabetes --; Obesity --; Aging --; Aortic Stenosis --; Hypertrophic Cardiomyopathy --; Restrictive Cardiomyopathy --; Constrictive Pericarditis --; Hypothyroidism --; PROGNOSIS OF DIASTOLIC HEART FAILURE --; SUMMARY --; REFERENCES --; 10 The Clinical Syndrome of Heart Failure --; INTRODUCTION --; EPIDEMIOLOGY Definition --; Classification --; Incidence and Prevalence --; Economics --; Risk Factors --; PATHOPHYSIOLOGY Normal Integrated Function of the Heart --; Heart Failure --; Systolic Heart Failure --; Diastolic Heart Failure --; DIAGNOSIS OF HEART FAILURE Symptoms and Signs --; Classification and Interpretation of the Clinical Presentation --; Diagnostic Laboratory Modalities --; COMMON CLINICAL FEATURES AND COMPLICATIONS --; Arrhythmias --; Functional Limitation and Exercise Capacity. Clinical Assessment of Functional and Exercise Capacity --; Mitral Regurgitation --; Sleep Apnea --; ''Cardiorenal'' Phenomena --; Cardiac Cachexia --; Anemia --; Psychiatric --; PROGNOSIS --; PREDICTION OF SURVIVAL --; CONCLUSION --; REFERENCES --; 11 Clinical Profiles and Prognosis in Heart Failure --; PURPOSES OF PROGNOSTIC FACTORS/FEATURES --; MAJOR OUTCOMES PREDICTED --; CLASSIFYING PROGNOSTIC FACTORS AND FEATURES --; MICROSCOPIC FEATURES --; VENTRICULAR STRUCTURE AND FUNCTION --; CENTRAL HEMODYNAMICS --; Filling Pressures --; Cardiac Output --; Clinical Assessment --; Biochemical Markers --; Markers of Dysrhythmia Risk --; CLINICAL INTEGRATORS Clinical Class --; FUNCTIONAL ASSESSMENT --; RESPONSES AFTER THERAPY --; SELECTION FOR END-STAGE THERAPIES --; THE PROGNOSIS FOR CHANGE --; REFERENCES --; 12 Conventional Therapy of Chronic Heart Failure: Diuretics, Angiotensin-Converting Enzyme Inhibitors, and Digoxin --; TREATMENT GOALS --; PHARMACOLOGIC THERAPY FOR SYSTOLIC HEART FAILURE Diuretics --; Vasodilator Therapy --; Digitalis --; REFERENCES --; 13 Conventional Therapy of Chronic Heart Failure: Beta-Adrenergic Blockers --; BENEFICIAL EFFECTS OF BETA ADRENERGIC BLOCKERS --; Exercise Tolerance --; Ventricular Remodeling --; DRUG CLASSES OF BETA BLOCKERS: ARE THESE DRUGS INTERCHANGEABLE? --; Effects on Mortality --; BETA BLOCKER USE IN SPECIAL POPULATIONS --; CLINICAL CONSIDERATIONS IN SELECTION OF A SPECIFIC BETA BLOCKER --; UNANSWERED QUESTIONS REGARDING BETA BLOCKER ADMINISTRATION Asymptomatic Left Ventricular Dysfunction --; Cardiac Pacemaker Implantation --; Concomitant Use with Inotropic Therapy --; CONCLUSION --; REFERENCES --; 14 Angiotensin Receptor Blockers for Heart Failure --; INTRODUCTION --; RATIONALE FOR THE USE OF ARBS IN HEART FAILURE --; WHY MIGHT THE EFFECTS OF ARBs AND ACE INHIBITORS DIFFER? ACE ''Breakthrough'' --; AT2 Receptor Stimulation.

Text of Note

This impressive guide authoritatively summarizes the fundamental cellular and molecular abnormalities associated with heart failure, as well as current invasive and noninvasive diagnostic techniques, the latest pharmacological advances, device-based therapies, surgical options, and evolving molecular treatments-surpassing any other text on the topic with concise discussions of recent molecular discoveries in pathophysiology alongside practical clinical approaches to the diagnosis and treatment of heart failure patients.

Heart failure.

Class number

Book number

G William Dec

G William Dec

Electronic name

[Book]

Y